ASP Isotopes Inc. (NASDAQ:ASPI) Sees Significant Increase in Short Interest

ASP Isotopes Inc. (NASDAQ:ASPI) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 277,300 shares, an increase of 15.0% from the February 29th total of 241,100 shares. Based on an average daily volume of 484,800 shares, the short-interest ratio is presently 0.6 days. Currently, 1.2% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, HC Wainwright raised their target price on shares of ASP Isotopes from $3.25 to $5.25 and gave the stock a “buy” rating in a research report on Thursday, February 29th.

ASP Isotopes Stock Down 4.0 %

Shares of ASPI stock opened at $4.13 on Monday. The firm has a market cap of $201.42 million, a price-to-earnings ratio of -9.18 and a beta of 5.10. The company’s 50 day moving average is $3.42 and its 200 day moving average is $2.16. ASP Isotopes has a 52-week low of $0.28 and a 52-week high of $4.97.

Insiders Place Their Bets

In related news, Director Robert John Andrew Ryan bought 15,596 shares of ASP Isotopes stock in a transaction dated Monday, January 29th. The shares were acquired at an average cost of $2.35 per share, with a total value of $36,650.60. Following the completion of the transaction, the director now owns 537,055 shares in the company, valued at approximately $1,262,079.25. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders bought a total of 18,246 shares of company stock valued at $41,801 over the last 90 days. Insiders own 26.30% of the company’s stock.

Hedge Funds Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently bought and sold shares of ASPI. Virtu Financial LLC purchased a new position in ASP Isotopes in the fourth quarter worth $26,000. Millennium Management LLC purchased a new position in ASP Isotopes in the fourth quarter worth $49,000. HTLF Bank purchased a new position in ASP Isotopes in the fourth quarter worth $141,000. Citadel Advisors LLC purchased a new position in ASP Isotopes in the fourth quarter worth $187,000. Finally, Rathbones Group PLC purchased a new position in ASP Isotopes in the fourth quarter worth $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry.